The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2.

Autor: Akhter J; Department of Surgery, St. George Hospital, Sydney, NSW 2217, Australia.; Mucpharm Pty Ltd., Sydney, NSW 2217, Australia., Quéromès G; CIRI, Centre International de Recherche en Infectiologie, Team VirPatH, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007 Lyon, France., Pillai K; Mucpharm Pty Ltd., Sydney, NSW 2217, Australia., Kepenekian V; Department of Surgery, St. George Hospital, Sydney, NSW 2217, Australia.; Hospices Civils de Lyon, EMR 3738 (CICLY), Lyon 1 Université, F-69921 Lyon, France., Badar S; Department of Surgery, St. George Hospital, Sydney, NSW 2217, Australia.; St. George & Sutherland Clinical School, University of New South Wales, Sydney, NSW 2217, Australia., Mekkawy AH; Department of Surgery, St. George Hospital, Sydney, NSW 2217, Australia.; Mucpharm Pty Ltd., Sydney, NSW 2217, Australia.; St. George & Sutherland Clinical School, University of New South Wales, Sydney, NSW 2217, Australia., Frobert E; CIRI, Centre International de Recherche en Infectiologie, Team VirPatH, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007 Lyon, France.; Laboratoire de Virologie, Institut des Agents Infectieux (IAI), Hospices Civils de Lyon, Groupement Hospitalier Nord, F-69004 Lyon, France., Valle SJ; Department of Surgery, St. George Hospital, Sydney, NSW 2217, Australia.; Mucpharm Pty Ltd., Sydney, NSW 2217, Australia.; St. George & Sutherland Clinical School, University of New South Wales, Sydney, NSW 2217, Australia., Morris DL; Department of Surgery, St. George Hospital, Sydney, NSW 2217, Australia.; Mucpharm Pty Ltd., Sydney, NSW 2217, Australia.; St. George & Sutherland Clinical School, University of New South Wales, Sydney, NSW 2217, Australia.
Jazyk: angličtina
Zdroj: Viruses [Viruses] 2021 Mar 06; Vol. 13 (3). Date of Electronic Publication: 2021 Mar 06.
DOI: 10.3390/v13030425
Abstrakt: Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection is the cause of a worldwide pandemic, currently with limited therapeutic options. The spike glycoprotein and envelope protein of SARS-CoV-2, containing disulfide bridges for stabilization, represent an attractive target as they are essential for binding to the ACE2 receptor in host cells present in the nasal mucosa. Bromelain and Acetylcysteine (BromAc) has synergistic action against glycoproteins by breakage of glycosidic linkages and disulfide bonds. We sought to determine the effect of BromAc on the spike and envelope proteins and its potential to reduce infectivity in host cells. Recombinant spike and envelope SARS-CoV-2 proteins were disrupted by BromAc. Spike and envelope protein disulfide bonds were reduced by Acetylcysteine. In in vitro whole virus culture of both wild-type and spike mutants, SARS-CoV-2 demonstrated a concentration-dependent inactivation from BromAc treatment but not from single agents. Clinical testing through nasal administration in patients with early SARS-CoV-2 infection is imminent.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje